Gain Therapeutics Q3 loss narrows as R&D costs fall
GANX•Gain Therapeutics reported a third-quarter net loss of $3.2 million, or $0.07 per share, as research and development and general and administrative expenses declined year over year. The company also reported long-term Phase 1b data showing no progression of Parkinson's motor symptoms.
1. Quarterly results
Gain Therapeutics said its third-quarter net loss narrowed year over year to $3.2 million, with a loss of $0.07 per share. Lower costs for the rexaceract program, pipeline optimization and personnel contributed to reduced research and development expenses; lower professional fees and personnel costs reduced general and administrative expenses.
2. Clinical plans
The company reported long-term Phase 1b data showing no progression of Parkinson's motor symptoms. It expects to initiate a Phase 2 trial of rexaceract in the first quarter of 2027 and plans to select an initial indication for GT-04686 in the fourth quarter of 2026.
